Kymera Therapeutics, Inc. (KYMR) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low35.0·High35.0
P/B Ratio
↓
4.52
+8% vs avg
5yr avg: 4.18
30Y Low2.7·High9.7
ROE
↑
-25.8%
↓+17% vs avg
5yr avg: -31.0%
30Y Low-44%·High-26%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KYMR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Kymera Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.9B | $6.6B | $3.0B | $1.5B | $1.3B | $3.0B | $2.8B | — | — |
| Enterprise Value | $6.6B | $6.3B | $3.0B | $1.5B | $1.3B | $3.0B | $2.7B | — | — |
| P/E Ratio → | -22.93 | — | — | — | — | — | — | — | — |
| P/S Ratio | 176.26 | 167.51 | 64.14 | 18.91 | 28.75 | 41.83 | 81.17 | — | — |
| P/B Ratio | 4.52 | 4.16 | 3.61 | 3.76 | 2.75 | 6.63 | 9.73 | — | — |
| P/FCF | — | — | — | — | — | — | 34.95 | — | — |
| P/OCF | — | — | — | — | — | — | 31.35 | — | — |
P/E links to full P/E history page with 30-year chart
KYMR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 160.50 | 63.45 | 18.59 | 27.66 | 41.42 | 80.79 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 34.79 | — | — |
KYMR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Kymera Therapeutics, Inc. earns an operating margin of -891.3%. Operating margins have compressed from -210.6% to -891.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -25.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 71.9% | — |
| Operating Margin | -891.3% | -891.3% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | -1438.5% | — |
| Net Profit Margin | -794.4% | -794.4% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | -1407.4% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.8% | -25.8% | -36.4% | -33.2% | -32.6% | -27.0% | -43.5% | — | — |
| ROA | -22.9% | -22.9% | -28.8% | -24.9% | -25.6% | -18.3% | -15.1% | -51.3% | -48.5% |
| ROIC | -24.9% | -24.9% | -33.5% | -30.7% | -27.8% | -21.5% | -49.0% | — | — |
| ROCE | -27.2% | -27.2% | -37.4% | -32.4% | -30.9% | -22.6% | -20.2% | -69.4% | -54.2% |
KYMR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $357M exceeds total debt of $82M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.11 | 0.21 | 0.04 | 0.04 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.17 | -0.04 | -0.06 | -0.10 | -0.07 | -0.05 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -0.16 | -3.16 | — |
| Interest Coverage | -1250.50 | -1250.50 | -898.03 | -748.81 | -878.59 | -571.67 | -395.46 | -895.65 | -1340.69 |
Net cash position: cash ($357M) exceeds total debt ($82M)
KYMR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Kymera Therapeutics, Inc.'s current ratio of 10.47x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.73x to 10.47x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.47 | 10.47 | 7.53 | 4.73 | 5.88 | 4.88 | 2.73 | 2.69 | 8.92 |
| Quick Ratio | 10.47 | 10.47 | 7.53 | 4.73 | 5.88 | 4.88 | 2.73 | 2.69 | 8.92 |
| Cash Ratio | 10.19 | 10.19 | 7.21 | 4.37 | 5.71 | 4.78 | 2.68 | 2.66 | 8.80 |
| Asset Turnover | — | 0.02 | 0.05 | 0.14 | 0.08 | 0.12 | 0.07 | 0.03 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 7.34 | 87.14 | 19.78 | 0.68 | 15.37 | — | — |
KYMR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Kymera Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 2.9% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $84M | $75M | $58M | $54M | $48M | $45M | $45M | $45M |
Peer Comparison
Compare KYMR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KYMRYou | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARVN | $652M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 VKTX | $4B | -9.9 | — | — | — | — | -47.3% | -44.4% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 SNY | $104B | 18.1 | 10.8 | 10.0 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
 BMY | $115B | 16.3 | 9.2 | 8.9 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See KYMR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KYMR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KYMR vs ARVN
Side-by-side business, growth, and profitability comparison vs Arvinas, Inc..
Start ComparisonKYMR — Frequently Asked Questions
Quick answers to the most common questions about buying KYMR stock.
What is Kymera Therapeutics, Inc.'s P/E ratio?
Kymera Therapeutics, Inc.'s current P/E ratio is -22.9x. This places it at the 50th percentile of its historical range.
What is Kymera Therapeutics, Inc.'s ROE?
Kymera Therapeutics, Inc.'s return on equity (ROE) is -25.8%. The historical average is -33.1%.
Is KYMR stock overvalued?
Based on historical data, Kymera Therapeutics, Inc. is trading at a P/E of -22.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Kymera Therapeutics, Inc.'s profit margins?
Kymera Therapeutics, Inc. has 100.0% gross margin and -891.3% operating margin.